Holen Sie sich die Stockscreener-App
278.38
1.63%
-4.62
Handel nachbörslich:
278.38
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$283.00
Offen:
$275.97
24-Stunden-Volumen:
3.39M
Relative Volume:
1.88
Marktkapitalisierung:
$56.56B
Einnahmen:
$310.23B
Nettoeinkommen (Verlust:
$1.69B
KGV:
32.29
EPS:
8.62
Netto-Cashflow:
$3.58B
1W Leistung:
-4.65%
1M Leistung:
-2.09%
6M Leistung:
+11.89%
1J Leistung:
+23.94%
1-Tages-Spanne:
$271.00
$278.69
1-Wochen-Bereich:
$271.00
$309.35
52-Wochen-Spanne:
$214.77
$309.35
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
278.38 | 56.56B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
687.52 | 88.38B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
148.62 | 36.28B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
70.47 | 8.10B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
7.15 | 626.70M | 10.42B | -38.77M | 323.54M | -0.51 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
JPMorgan Adjusts Price Target on Cencora to $326 From $301, Maintains Overweight Rating - marketscreener.com
Beat the Market the Zacks Way: Limbach, Stride, Cencora in Focus - Yahoo Finance
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - Yahoo Finance
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Cencora increases FY2025 EPS guidance to $15.70-$15.95 amid specialty growth - MSN
Here's Why Cencora (COR) is a Strong Momentum Stock - Yahoo Finance
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Citigroup Maintains Buy Rating and Raises Price Target for Cencora (COR) | COR Stock News - GuruFocus
Cencora (COR) Reaches New Heights with Increased Price Target | COR Stock News - GuruFocus
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Cencora (COR) Receives Increased Price Target from Baird Analyst | COR Stock News - GuruFocus
Cencora (COR) Price Target Increased as U.S. Results Impress | COR Stock News - GuruFocus
Cencora Inc (COR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Full-Year ... - Yahoo Finance
Cencora Earnings: Strong Utilization and GLP-1s Maintain Growth Momentum and RCA Expands Margins - Morningstar
Cencora Inc (COR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Full-Year Guidance - GuruFocus
Cencora, Inc. Reports Strong Q2 2025 Results - TipRanks
Earnings call transcript: Cencora Inc Q1 2025 beats earnings expectations, stock surges - Investing.com Nigeria
Cencora: Fiscal Q2 Earnings Snapshot - Midland Daily News
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Earnings call transcript: Cencora Inc Q1 2025 beats earnings expectations, stock surges By Investing.com - Investing.com South Africa
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Q2 2025 slides: adjusted EPS jumps 16.3%, guidance raised By Investing.com - Investing.com South Africa
Cencora Enjoys Strong Momentum From GLP-1s, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora (NYSE:COR) Sees Strong Q2 Earnings Surge; Declares US$0.55 Dividend - simplywall.st
Jim Cramer Rediscovers Love For Magnificent 7 & Discusses These 11 Stocks - Insider Monkey
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings - Benzinga
Jim Cramer on Cencora, Inc. (COR): ‘Middleman Money Machine Silences the Doubters’ - MSN
Cencora, Inc. SEC 10-Q Report - TradingView
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised - TradingView
Transcript : Cencora, Inc., Q2 2025 Earnings Call, May 07, 2025 - marketscreener.com
Cencora Inc (COR) Sees Significant Stock Price Increase | COR Stock News - GuruFocus
Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
Cencora, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:COR) - Seeking Alpha
Cencora Ups Profit Forecast Thanks To Drug Demand - Finimize
Cencora Exceeds EPS Estimates, Achieves Revenue Goals in Q1 2025News and Statistics - IndexBox
Cencora Q2 2025 slides: adjusted EPS jumps 16.3%, guidance raised - Investing.com
Cencora (COR) Misses Q2 Revenue Expectations but Highlights Strong Market Role | COR Stock News - GuruFocus
Cencora (COR) Updates FY25 Guidance with Focus on U.S. Earnings Growth | COR Stock News - GuruFocus
Cencora Reports Strong Q2 2025 Financial Results - TipRanks
Cencora Inc (COR) Q2 2025 Earnings: EPS Surpasses Estimates at $3.68, Revenue Falls Short at $75.5 Billion - GuruFocus
Cencora Inc earnings beat by $0.36, revenue topped estimates - Investing.com South Africa
Cencora Reports Fiscal 2025 Second Quarter Results | COR Stock News - GuruFocus
Earnings Flash (COR) CENCORA Posts Q2 Adjusted EPS $4.42, vs. FactSet Est of $4.11 - marketscreener.com
Cencora, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025 - marketscreener.com
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics - MSN
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates? - TradingView
Those who invested in Cencora (NYSE:COR) five years ago are up 253% - simplywall.st
Cencora to support US launch of Neurotech’s cell therapy, ENCELTO - Ophthalmology Times
Cencora (COR) Earnings Expected to Grow: Should You Buy? - Yahoo
UBS Adjusts Price Target on Cencora to $335 From $298, Maintains Buy Rating - marketscreener.com
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):